Written by While traditional hERG inhibition testing has effectively prevented cardiotoxic drugs from entering the market, current regulatory frameworks are evolving to provide a more comprehensive assessment of cardiac risk. As outlined in the hERG Screening Market Outlook, the transition toward multi-channel cardiac safety testing and stem-cell-derived cardiomyocyte models is reshaping the future of preclinical cardiotoxicity evaluation.
The CiPA Initiative: Moving Beyond Isolated hERG Testing
A key driver of change in cardiotoxicity testing is the Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative.